Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
95
resultados
Última actualización
26/02/2026 [07:06:00]
Resultados 25 a 50 de 95
Resumen de: WO2026029035A1
The purpose of the present invention is to provide an antibody against a coronavirus (SARS-CoV-2) mutant strain, in particular, an omicron substrain. Moreover, another purpose of the present invention is to provide a pharmaceutical composition against coronavirus infections, the pharmaceutical composition using said antibody. The present invention provides: an antibody that binds to a spike protein of coronavirus and has the ability to neutralize coronavirus including an omicron substrain, or an antigen-binding fragment thereof; and a pharmaceutical composition for preventing or treating coronavirus infections, the pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.
Resumen de: EP4686470A1
The present invention refers to macrocyclic peptides as covalent reversible inhibitors of SARS-CoV-2 M<sup>pro</sup> with a potential broad-spectrum activity against CoV proteases. The compounds are therefore indicated for treating M<sup>pro</sup> associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
Resumen de: WO2026023869A1
The present application relates to a vaccine composition comprising peptides isolated from structural proteins of SARS-CoV-2.
Resumen de: MX2024009232A
The present application is in the field of genetic engineering, biotechnological and in particular in the design and production of synthetic genes in different strains of Escherichia coli resulting in soluble molecules with antigenic capacity against the SARS-CoV2 virus. This method is summarized in three phases which are: The application of molecular engineering for obtaining the DNA sequence that allows E coli to produce SARS-CoV2 viral antigens, followed by integration of the designed vector into E coli cells to obtain recombinant strains and finally the production and purification of recombinant viral antigens of SARS-CoV2 in E coli.
Resumen de: WO2026023870A1
The present application relates to a method for extracting epitopes effective in the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising the steps of: (a) extracting, from an anti-spike antibody database, first structural data including known structures and second structural data including unknown structures, and extracting, from a SARS-CoV-2 proteome database, third structural data including known structures; (b) carrying out 3D modeling on the second structural data, and classifying the third structural data into a first group including structural proteins and a second group including both structural proteins and non-structural proteins; (c) carrying out spike-antibody docking on the basis of the first group and the second structural data on which 3D modeling has been carried out; (d) constructing a spike-antibody database on the basis of the first structural data and the docked data, and predicting conformational epitopes on the basis of the second group; (e) characterizing epitopes on the basis of the spike-antibody database and the conformational epitopes; and (f) selecting final epitopes on the basis of analysis results.
Resumen de: MX2025014589A
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).
Resumen de: MX2025011740A
An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.
Resumen de: NZ791834A
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject.
Resumen de: RS20240787A1
Method and device for applying an electrical stimulus to an acupuncture point using an electrode connected to ground on a patient exposed to the emitted electromagnetic field of a Tesla transformer. The intention of the invention is increasing the effectiveness of acupuncture treatment, while making its use painless for the general population, and especially suitable for the pediatric population. The device can be used to relieve symptoms and pain caused by trauma, post-Covid 19 syndrome, for prevention of worsening of such symptoms, for the prevention and treatment of symptoms associated with depression and other psychiatric, neurological and developmental disorders, including major depressive disorder, Alzheimer's disease and autism. The device consists of a Tesla transformer (1) and an electrode or set of electrodes (6) connected to an electrical ground (4). The Tesla transformer (1) consists of a primary coil (1.a), a secondary coil (1.b), a feedback coil (1.c) and a control circuit (2). The system also includes a variable resistor (7), which regulates the radiation intensity of the Tesla transformer (1).
Resumen de: US20260028673A1
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS-Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.
Resumen de: US20260028685A1
In one aspect, the inventive technology relates to improved systems, methods, and compositions for a novel saliva stabilization solution for use in nucleic acid amplification reactions, and in particular embodiment its use in the detection of pathogen nucleic acids, such as SARS-CoV-2 (COVID-19).
Resumen de: US20260028644A1
Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.
Resumen de: AU2024335376A1
The present disclosure relates to in vitro identification of neutralizing antibody against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Specifically, the present disclosure relates a kit and an in vitro assay for analyzing the presence of neutralizing antibody/inhibitors which could block or inactivate receptor binding domain of the spike protein of SARS-CoV-2.
Resumen de: WO2026023870A1
The present application relates to a method for extracting epitopes effective in the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising the steps of: (a) extracting, from an anti-spike antibody database, first structural data including known structures and second structural data including unknown structures, and extracting, from a SARS-CoV-2 proteome database, third structural data including known structures; (b) carrying out 3D modeling on the second structural data, and classifying the third structural data into a first group including structural proteins and a second group including both structural proteins and non-structural proteins; (c) carrying out spike-antibody docking on the basis of the first group and the second structural data on which 3D modeling has been carried out; (d) constructing a spike-antibody database on the basis of the first structural data and the docked data, and predicting conformational epitopes on the basis of the second group; (e) characterizing epitopes on the basis of the spike-antibody database and the conformational epitopes; and (f) selecting final epitopes on the basis of analysis results.
Resumen de: WO2026023869A1
The present application relates to a vaccine composition comprising peptides isolated from structural proteins of SARS-CoV-2.
Resumen de: WO2026021236A1
Provided are a polypeptide capable of inhibiting a MERS-like coronavirus infection, and a use thereof. On the basis of a membrane fusion invasion feature mediated by an S2 subunit of a MjHKU4r-CoV coronavirus S protein, a group of polypeptides are invented by using the HR1 functional domain of the protein as a target. The polypeptides can efficiently inhibit the membrane fusion invasion process of a MERS-like coronavirus MjHKU4r-CoV. By competitively binding to a viral HR1 functional domain, these polypeptides inhibit the formation of a viral 6-helix bundle (6-HB) fusion core, thereby efficiently blocking the process of the coronavirus MjHKU4r-CoV invading a target cell. The present invention can provide an efficient preventive and therapeutic candidate drug for prevention and treatment of the MERS-like coronavirus MjHKU4r-CoV having potential high pathogenicity and cross-species transmission.
Resumen de: US20260029316A1
An immunochromatographic method for a trace amount of an antigen or an antibody such as SARS-COV-2 including use of saliva, enabling highly sensitive immunochromatographic antigen or antibody detection even when the saliva is used. A method for pretreatment of a specimen for an immunochromatographic test, including passing the saliva through a porous member capable of supporting a viscous component in the saliva to remove the viscous component, passing the liquid that has passed through the porous member through a filter having a hole diameter of from 0.1 μm to 10 μm, and concentrating an antigen or an antibody in the liquid that has passed through the filter.
Resumen de: EP4684778A1
Provided is a pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and an auxiliary material. The auxiliary material comprises one or more of a filler, a binder, a glidant, a disintegrant and a lubricant. The pharmaceutical composition has the feasibility of preparation process, excellent properties of preparations, good stability and good dissolution, and meets the pharmaceutical standards.
Resumen de: WO2026018922A1
The purpose of the present disclosure is to provide highly versatile, ready-to-deliver allogenic T cells for novel coronavirus infection, and a production method therefor. The present invention provides: a method for producing a cell population for the treatment and/or prevention of SARS-CoV-2 infection and including T cells or precursor T cells that express a human T cell receptor (TCR) specific to SARS-CoV-2, said method comprising a step for causing the expression of one or more human TCRs specific to SARS-CoV-2 in T cells or precursor T cells in vitro; and a cell population for the treatment and/or prevention of SARS-CoV-2 infection and produced via said method, said cell population comprising allogenically derived T cells or precursor T cells.
Resumen de: WO2026018060A1
The present invention in general relates to a pharmaceutical formulation, specifically a dry powder inhalation formulation for treatment of Corona virus disease-19 (COVID-19). The formulation comprises of combination of an antiviral and a corticosteroid. The invention further describes the method of preparation of the dry powder inhalation formulation.
Resumen de: WO2026016695A1
Disclosed is use of coronavirus SL5s as targets in the preparation of a drug for preventing and treating coronavirus infection. The drug target coronavirus SL5s described in the present invention are the stem-loops 5 of the 5'UTR regions of coronaviruses, which participate in regulating viral mRNA translation. Further disclosed is an inhibitor of the SL5s of 7 human infectious coronaviruses, i.e., an antisense oligonucleotide specifically targeting the SL5s for inhibiting coronavirus infection. Experiments have demonstrated that the application of the antisense oligonucleotide specifically targeting the coronavirus SL5s in vitro can significantly inhibit the translation levels of the coronavirus mRNAs. The coronavirus SL5s described in the present invention can be used as drug targets to screen for candidate drugs for inhibiting coronavirus mRNA translation, showing great significance for the development of anti-coronavirus drugs and the prevention and treatment of coronaviruses in the future.
Resumen de: AU2025283673A1
Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and capture probes, for detection of SARS-CoV-2 nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding formulations, reaction mixtures, and kits and related methods for preparing aqueous reaction mixtures from dried formulations. ec e c
Resumen de: AU2024308469A1
Disclosed are glycanic compounds and their use for treating or inhibiting the development of a viral infection in a subject, especially a coronavirus infection, such as a SARS-CoV-2 infection, or for treating conditions associated with viral infections, such as an acute inflammatory condition, cytokine release syndrome (CRS) or a cytokine storm, severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS).
Resumen de: WO2026017760A1
5 A composition in oral dosage form comprises tryptophan or at least one tryptophan intermediate, and at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and/or (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. The composition may include a cohort of bacteria 10 including at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and at least one bacterium that (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. Typically, the cohort of bacteria is capable of producing the immunomodulatory indole derivatives indole-3-lactic acid (ILA), 15 indole-3-propionic acid (IPA) and indole acrylic acid (IA). The composition finds utility in inhibition or prevention of immune-mediated inflammatory damage in subjects with an immune-mediated infectious or non-infectious disease, and in particular can prevent a severe inflammatory response or incidence of Long Covid in SARS-CoV-19 subjects. 20 (Figure 16)
Nº publicación: US20260022111A1 22/01/2026
Solicitante:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV [US]
AARHUS UNIV [DK]
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY,
AARHUS UNIVERSITY
Resumen de: US20260022111A1
Provided herein are compounds having a structure of formula (I) or formula (II):or a pharmaceutically acceptable salt, solvate, or hydrate thereof, useful in treating or preventing coronavirus infection. In some embodiments, the coronavirus infection is COVID-19 (SARS-COV-19). Also provided are compositions comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus infection.
BOPI
Sede Electrónica
